ALK and neuroblastoma: The second and the third generations of ALK TKIs, such as ceritinib, alectinib, brigatinib, and lorlatinib, have been widely tested in both preclinical and clinical NB settings and have shown greater potency than crizotinib [26,27,28,29,30,31,32,33,34].